Saffron Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-06-2024
- Paid Up Capital ₹ 0.10 M
as on 23-06-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 56.16%
(FY 2023)
- Profit -31.02%
(FY 2023)
- Ebitda -27.10%
(FY 2023)
- Net Worth 11.79%
(FY 2023)
- Total Assets -12.60%
(FY 2023)
About Saffron Therapeutics
- CIN/LLPIN
U24233GJ2014PTC080089
- Company No.
080089
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Saffron Therapeutics Private Limited offer?
Saffron Therapeutics Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Pharmaceutical Syrup, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Health Conditions, Stomach Care.
Who are the key members and board of directors at Saffron Therapeutics?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Singh  | Director | 10-Jul-2014 | Current |
| Ram Magar | Director | 29-Sep-2016 | Current |
| Anilkumar Negi | Director | 10-Jul-2014 | Current |
| Hiren Patel | Director | 25-Nov-2014 | Current |
Financial Performance of Saffron Therapeutics.
Saffron Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 56.16% increase. The company also saw a substantial fall in profitability, with a 31.02% decrease in profit. The company's net worth Soared by an impressive increase of 11.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saffron Therapeutics?
In 2023, Saffron Therapeutics had a promoter holding of 40.84% and a public holding of 59.16%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saffron Formulations Private LimitedActive 9 years 7 monthsAmit Singh and Hiren Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Saffron Therapeutics?
Saffron Therapeutics has a workforce of 1 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saffron Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saffron Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
